News: 2021
ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines
May 04, 2021
The Nature Reviews Cancer paper summarizes key insights gleaned from previous successful and non-successful therapeutic vaccine...
Read more
ISA has relocated to brand new Biopartner 5 building
May 03, 2021
ISA has relocated to brand new Biopartner 5 building
Read more
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors
May 03, 2021
First patient has been treated in its phase 1/2 dose escalation and expansion trial evaluating MCLA-129 for the treatment of pa...
Read more
Modra Pharmaceuticals Appoints Two New Supervisory Board Members Adding Significant Experience in Corporate and Clinical Development
April 27, 2021
Modra Pharmaceuticals Appoints Two New Supervisory Board Members
Read more
InteRNA Technologies Publishes Preclinical Data from Investigational microRNA INT-1B3 Program in Molecular Therapy - Nucleic Acids and Oncotarget
March 24, 2021
Results further support the potential of lead candidate, INT-1B3, as novel option for
therapeutic intervention in oncology
Read more
InteRNA Technologies Awarded € 2.7M Clinical Innovation Credit from Dutch Government
March 11, 2021
This award will support the clinical validation of the Company's lead candidate, INT-1B3, for the treatment of solid tumors.
Read more
ORCA Therapeutics B.V. to Start Highest Scheduled Dose in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patients. Consistent Efficacy Data from First Cohort and Start New Indication. Additional funding secured.
March 05, 2021
ORCA Therapeutics B.V. to Start Highest Scheduled Dose in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patie...
Read more
ISA Pharmaceuticals selects product candidate for clinical trial with first in class COVID-19 immunotherapy
March 03, 2021
ISA106's promising results in preclinical tests warrant fast entry into human studies to address the need for effective COVID-1...
Read more
InteRNA Technologies Announces Dosing of First Patient in First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors
February 16, 2021
-- Phase 1 study to investigate safety and preliminary efficacy of lead candidate, INT-1B3 --
Read more
Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting
February 12, 2021
Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting
Read more
InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M
February 09, 2021
-- Proceeds to advance clinical evaluation of lead candidate INT-1B3 and further preclinical drug candidates towards the clinic --
Read more
First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals' Lead Immunotherapy ISA101b with Keytruda®
January 26, 2021
Combination aimed at priming and driving durable patient immune responses to cancer
Read more
Sapreme Appoints Henrik Luessen as Chief Business Officer
January 21, 2021
Appointment of Henrik L. Luessen, Ph.D., as Chief Business Officer at Sapreme
Read more
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
January 19, 2021
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a...
Read more
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial
January 12, 2021
Merus N.V. today announced collaborations with nationwide medical organizations in the Netherlands and Japan to raise awareness...
Read more
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
January 11, 2021
Clinical data from Phase 1 dose escalation study of MCLA-158 will be presented in a poster session at the American Society of C...
Read more
ISA106 - SLP therapeutic for COVID-19
January 11, 2021
Interview with ISA Pharmaceuticals' CSO, Professor Kees Melief on the need for a therapeutic that specifically drives the T cel...
Read more
Macrophage Pharma expands Executive team with CSO and CTO
January 09, 2021
Key hires enhance management for next development phase
Read more
Klinische Fase 1a studie met lead compound INT-1B3
January 07, 2021
December 2020: Net voor Kerst in de bijlage van Het Algemeen Dagblad - InteRNA heeft klinische Fase 1a studie met lead compound...
Read more
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
January 07, 2021
NRG1 fusions are rare mutations in many types of solid tumors, including non-small cell lung cancer and pancreatic cancer
Read more
